Hyaluronic acid in the evaluation of liver fibrosis in patients with hepatitis C on haemodialysis

Brazilian Journal of Infectious Diseases

Renata Eliane De Ávila¹  Ricardo Andrade Carmo²  Kátia De Paula Farah²  Antônio Lúcio Teixeira²  Lucas Viana Coimbra²  Carlos Maurício De Figueiredo Antunes²  José Roberto Lambertucci¹ 

[1] ,Universidade Federal de Minas Gerais Faculdade de Medicina Núcleo de Ações e Pesquisa em Apoio Department of Internal Medicine

关键词: liver fibrosis;    hyaluronic acid;    end-stage renal disease;    haemodialysis;    hepatitis C;   

DOI  :  10.1590/S1413-86702010000400004

来源: SciELO

【 摘 要 】

BACKGROUND: This study evaluated the role of HA as a marker of liver fibrosis in patients with hepatitis C on haemodialysis. METHODS: This is a cross-sectional study in which 52 patients were divided into two groups: Group 1: patients with hepatitis C and end-stage renal disease (ESRD) undergoing haemodialysis (n = 23); and Group 2: patients with hepatitis C without ESRD (n = 29). Plasma levels of HA were associated with histological data of the samples obtained by liver biopsy and classified by METAVIR group scoring system. RESULTS: Higher plasma levels were significantly correlated to significant liver fibrosis (METAVIR > F2). In Group 1, the HA cutoff to discriminate significant fibrosis was 984.8 ng/mL, with accuracy, sensitivity and specificity of 80.8%, 83.0%, and 70.0%, respectively. In Group 2, the HA cutoff was 222.3 ng/mL, with accuracy, sensitivity and specificity of 74.5%, 70.0%, and 94.0%, respectively. CONCLUSION: HA was an accurate noninvasive marker in predicting significant fibrosis in patients with hepatitis C on haemodialysis.

【 授权许可】

CC BY-NC-ND   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License